Mitochondria-targeted antioxidant mitotempo protects mitochondrial function against amyloid beta toxicity in primary cultured mouse neurons

Biochemical and Biophysical Research Communications

Volumn 478, Issue 1, 2016, Pages 174-180

  Hu, Hongtao ^a   Li, Mo ^a  

^a Jishuitan Orthopaedic College of Tsinghua University   (China)

Author keywords

Alzheimer's disease; Amyloid beta; Mitochondria targeted antioxidant; Mitochondrial dysfunction; Mitotempo

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; ANTIOXIDANT; CYTOCHROME C OXIDASE; DNA DIRECTED DNA POLYMERASE GAMMA; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL DNA; MITOTEMPO; PROTEIN; SINGLE STRANDED DNA BINDING PROTEIN; SINGLE STRANDED DNA BINDING PROTEIN 1; TWINKLE PROTEIN; UNCLASSIFIED DRUG; ORGANOPHOSPHORUS COMPOUND; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BIOENERGY; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; LIPID OXIDATION; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL DNA REPLICATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NERVE CELL CULTURE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIMARY CELL CULTURE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; NERVE CELL; PHYSIOLOGY; ULTRASTRUCTURE;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MITOCHONDRIA; NEURONS; ORGANOPHOSPHORUS COMPOUNDS; OXIDATIVE STRESS; PIPERIDINES;

EID: 84980407672     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.07.071     Document Type: Article

References (39)

1. [1] Querfurth, H.W., LaFerla, F.M., Alzheimer's disease. N. Engl. J. Med. 362 (2010), 329–344.
2. [2] Reddy, P.H., Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol., 2006, 2006, 31372.
3. [3] Reddy, P.H., Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid. Redox Signal 9 (2007), 1647–1658.
4. [4] Du, H., Guo, L., Yan, S., Sosunov, A.A., McKhann, G.M., Yan, S.S., Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 18670–18675.
5. [5] Moreira, P.I., Carvalho, C., Zhu, X., Smith, M.A., Perry, G., Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim. Biophys. Acta 1802 (2010), 2–10.
6. [6] Swerdlow, R.H., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp. Neurol. 218 (2009), 308–315.
7. [7] Wang, X., Su, B., Siedlak, S.L., Moreira, P.I., Fujioka, H., Wang, Y., Casadesus, G., Zhu, X., Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 19318–19323.
8. [8] Gibson, G.E., Sheu, K.F., Blass, J.P., Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm. (Vienna) 105 (1998), 855–870.
9. [9] Castellani, R., Hirai, K., Aliev, G., Drew, K.L., Nunomura, A., Takeda, A., Cash, A.D., Obrenovich, M.E., Perry, G., Smith, M.A., Role of mitochondrial dysfunction in Alzheimer's disease. J. Neurosci. Res. 70 (2002), 357–360.
10. [10] McManus, M.J., Murphy, M.P., Franklin, J.L., The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 31 (2011), 15703–15715.
11. [11] Calkins, M.J., Manczak, M., Reddy, P.H., Mitochondria-targeted antioxidant SS31 prevents amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease. Pharm. (Basel) 5 (2012), 1103–1119.
12. [12] Polidori, M.C., Nelles, G., Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease - challenges and perspectives. Curr. Pharm. Des. 20 (2014), 3083–3092.
13. [13] Behl, C., Moosmann, B., Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic. Biol. Med. 33 (2002), 182–191.
14. [14] Mao, P., Manczak, M., Shirendeb, U.P., Reddy, P.H., MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochim. Biophys. Acta 1832 (2013), 2322–2331.
15. [15] Jia, Y.L., Sun, S.J., Chen, J.H., Jia, Q., Huo, T.T., Chu, L.F., Bai, J.T., Yu, Y.J., Yan, X.X., Wang, J.H., SS31, a small molecule antioxidant peptide, attenuates beta-amyloid elevation, mitochondrial/synaptic deterioration and cognitive deficit in SAMP8 mice. Curr. Alzheimer Res. 13 (2016), 297–306.
16. [16] Liang, H.L., Sedlic, F., Bosnjak, Z., Nilakantan, V., SOD1 and MitoTEMPO partially prevent mitochondrial permeability transition pore opening, necrosis, and mitochondrial apoptosis after ATP depletion recovery. Free Radic. Biol. Med. 49 (2010), 1550–1560.
17. [17] Lu, L., Guo, L., Gauba, E., Tian, J., Wang, L., Tandon, N., Shankar, M., Beck, S.J., Du, Y., Du, H., Transient cerebral ischemia promotes brain mitochondrial dysfunction and exacerbates cognitive impairments in young 5xFAD mice. PLoS One, 10, 2015, e0144068.
18. [18] Koekemoer, T.C., Downing, T.G., Oelofsen, W., An alternative PCR assay for quantifying mitochondrial DNA in crude preparations. Nucleic Acids Res. 26 (1998), 2829–2830.
19. [19] Guo, L.D., Chen, X.J., Hu, Y.H., Yu, Z.J., Wang, D., Liu, J.Z., Curcumin inhibits proliferation and induces apoptosis of human colorectal cancer cells by activating the mitochondria apoptotic pathway. Phytother. Res. 27 (2013), 422–430.
20. [20] Mukhopadhyay, P., Rajesh, M., Hasko, G., Hawkins, B.J., Madesh, M., Pacher, P., Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat. Protoc. 2 (2007), 2295–2301.
21. [21] Indo, H.P., Tomiyoshi, T., Suenaga, S., Tomita, K., Suzuki, H., Masuda, D., Terada, M., Ishioka, N., Gusev, O., Cornette, R., Okuda, T., Mukai, C., Majima, H.J., MnSOD downregulation induced by extremely low 0.1 mGy single and fractionated X-rays and microgravity treatment in human neuroblastoma cell line, NB-1. J. Clin. Biochem. Nutr. 57 (2015), 98–104.
22. [22] Yao, J., Brinton, R.D., Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. Curr. Pharm. Des. 17 (2011), 3474–3479.
23. [23] Venable, P.W., Taylor, T.G., Sciuto, K.J., Zhao, J., Shibayama, J., Warren, M., Spitzer, K.W., Zaitsev, A.V., Detection of mitochondrial depolarization/recovery during ischaemia–reperfusion using spectral properties of confocally recorded TMRM fluorescence. J. Physiol. 591 (2013), 2781–2794.
24. [24] Brown, G.C., Nitric oxide as a competitive inhibitor of oxygen consumption in the mitochondrial respiratory chain. Acta Physiol. Scand. 168 (2000), 667–674.
25. [25] Kukreja, L., Kujoth, G.C., Prolla, T.A., Van Leuven, F., Vassar, R., Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer's disease. Mol. Neurodegener., 9, 2014, 16.
26. [26] Kamat, P.K., Kalani, A., Rai, S., Swarnkar, S., Tota, S., Nath, C., Tyagi, N., Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer's disease: understanding the therapeutics strategies. Mol. Neurobiol. 53 (2016), 648–661.
27. [27] Wang, X., Wang, W., Li, L., Perry, G., Lee, H.G., Zhu, X., Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim. Biophys. Acta 1842 (2014), 1240–1247.
28. [28] Bobba, A., Petragallo, V.A., Marra, E., Atlante, A., Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease. Int. J. Alzheimers Dis., 2010, 2010.
29. [29] Ferreira, M.E., de Vasconcelos, A.S., da Costa Vilhena, T., da Silva, T.L., da Silva Barbosa, A., Gomes, A.R., Dolabela, M.F., Percario, S., Oxidative stress in Alzheimer's disease: should we keep trying antioxidant therapies?. Cell Mol. Neurobiol. 35 (2015), 595–614.
30. [30] Beck, S.J., Guo, L., Phensy, A., Tian, J., Wang, L., Tandon, N., Gauba, E., Lu, L., Pascual, J.M., Kroener, S., Du, H., Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer's disease. Nat. Commun., 7, 2016, 11483.
31. [31] Kish, S.J., Brain energy metabolizing enzymes in Alzheimer's disease: alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase. Ann. N. Y. Acad. Sci. 826 (1997), 218–228.
32. [32] Du, H., Guo, L., Fang, F., Chen, D., Sosunov, A.A., McKhann, G.M., Yan, Y., Wang, C., Zhang, H., Molkentin, J.D., Gunn-Moore, F.J., Vonsattel, J.P., Arancio, O., Chen, J.X., Yan, S.D., Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 14 (2008), 1097–1105.
33. [33] Lustbader, J.W., Cirilli, M., Lin, C., Xu, H.W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., Trinchese, F., Liu, S., Gunn-Moore, F., Lue, L.F., Walker, D.G., Kuppusamy, P., Zewier, Z.L., Arancio, O., Stern, D., Yan, S.S., Wu, H., ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304 (2004), 448–452.
34. [34] Mari, M., Morales, A., Colell, A., Garcia-Ruiz, C., Kaplowitz, N., Fernandez-Checa, J.C., Mitochondrial glutathione: features, regulation and role in disease. Biochim. Biophys. Acta 1830 (2013), 3317–3328.
35. [35] Hudson, G., Chinnery, P.F., Mitochondrial DNA polymerase-gamma and human disease. Hum. Mol. Genet. 15:Spec No 2 (2006), R244–R252.
36. [36] Mancuso, M., Orsucci, D., Siciliano, G., Murri, L., Mitochondria, mitochondrial DNA and Alzheimer's disease. What comes first?. Curr. Alzheimer Res. 5 (2008), 457–468.
37. [37] Santos, R.X., Correia, S.C., Zhu, X., Smith, M.A., Moreira, P.I., Castellani, R.J., Nunomura, A., Perry, G., Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease. Antioxid. Redox Signal 18 (2013), 2444–2457.
38. [38] Wang, J., Xiong, S., Xie, C., Markesbery, W.R., Lovell, M.A., Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J. Neurochem. 93 (2005), 953–962.
39. [39] Lewis, W., Copeland, W.C., Day, B.J., Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab. Invest 81 (2001), 777–790.